If You Invested in Putnam BioRevolution ETF (SYNB)
Looking for the current price? See the SYNB quote & overviewWhat $1,000 or $10,000 in SYNB Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Sep 30, 2022 |
|---|---|---|---|---|
| $1,000 | $1,074 +7% | — | — | $1,275 +27% |
| $10,000 | $10,745 +7% | — | — | $12,748 +27% |
Based on real historical closing prices, dividend- and split-adjusted, through 2025-11-13. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for SYNB$1,000 Investment Over Time
SYNB vs S&P 500Year-by-Year Returns
SYNB annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2022 | $24.80 | $25.97 | +4.7% | +4.7% |
| 2023 | $25.95 | $29.10 | +12.1% | +17.4% |
| 2024 | $29.06 | $29.57 | +1.8% | +19.3% |
| 2025 | $29.64 | $31.61 | +6.7% | +27.5% |
About Putnam BioRevolution ETF
NYSE
The ticker SYNB represents the Putnam BioRevolution ETF, an exchange-traded fund identified in public communications as Putnam BioRevolution ETF (SYNB). According to a Business Wire announcement issued by Franklin Templeton, the fund is scheduled to be liquidated and dissolved. The announcement explains that the liquidation is anticipated to occur on or about November 21, 2025, with related trading and order activity ceasing ahead of that date.
The Putnam BioRevolution ETF (SYNB) is associated with Franklin Templeton, which is described in the same announcement as a global investment management organization whose subsidiaries operate under the Franklin Templeton name. The communication notes that Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions, and that it offers capabilities in equity, fixed income, alternatives and multi-asset solutions through its specialist investment managers.
The liquidation plan for SYNB includes several key steps described in the announcement. Effective as of the close of business on October 24, 2025, the fund will no longer accept orders for the purchase of creation units. Effective as of the close of business on November 13, 2025, the fund will no longer accept redemption orders. Trading for the fund on NYSE Arca, Inc. (NYSE Arca) is expected to be suspended prior to market open on November 14, 2025.
Following the suspension of trading and the cessation of purchases and redemptions, the announcement states that, as soon as reasonably practicable on or after the liquidation date, the fund will liquidate its remaining assets after payment or provision for charges, taxes, expenses and liabilities. After any dividend determinations, the fund intends to distribute cash pro rata to all remaining shareholders as of the liquidation date who have not previously redeemed all of their shares. The announcement notes that proceeds of the liquidation are currently scheduled to be sent to shareholders on or about November 21, 2025, and that shareholders should consult their tax advisors about the tax implications of the liquidation.
Franklin Resources, Inc., which is identified with the NYSE ticker BEN in the same announcement, is described as a California-based company with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. The announcement highlights that Franklin Templeton brings extensive capabilities in equity, fixed income, alternatives and multi-asset solutions, and that it has many investment professionals and offices in major financial markets around the world. These details provide context for the asset management group responsible for the Putnam BioRevolution ETF (SYNB).
Because the fund is in the process of being liquidated and dissolved, SYNB should be understood in a historical and transitional context. The Business Wire announcement outlines a defined timeline for the end of trading, the halt of creation and redemption activity, and the distribution of liquidation proceeds to shareholders. Investors and observers reviewing SYNB as a symbol can use this information to understand that the fund is not being positioned for ongoing operation, but instead is moving through a planned wind-down process as described in the Franklin Templeton communication.
Frequently Asked Questions
Putnam BioRevolution ETF investment returns
How much would $1,000 invested in Putnam BioRevolution ETF be worth today?
If you invested $1,000 in Putnam BioRevolution ETF (SYNB) 1 years ago on 2025-08-04, your investment would be worth $1,074 as of 2025-11-13, representing a +7.4% total return, growing at a compounded rate of 29.7% per year (CAGR).
Has Putnam BioRevolution ETF outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare SYNB performance over available time periods.
What is Putnam BioRevolution ETF's average annual return?
The compound annual growth rate (CAGR) of SYNB over the past 1 years is 29.7%, growing at a compounded rate each year. Individual years vary significantly — SYNB's best recent year was 2023 (+12.1%) and worst was 2024 (+1.8%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
